Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved.
Multiple sclerosis: Rapid screening for remyelination-promoting drugs using micropillar arrays.
Development of the Cell Population in the Brain White Matter of Young Children.
Risk factors for idiopathic optic neuritis recurrence.
Psychiatric disorders revealing multiple sclerosis after 20 years of evolvement.
Demyelinating disease: Is TOPIC the last trial for clinically isolated syndrome?
Accuracy of a custom physical activity and knee angle measurement sensor system for patients with neuromuscular disorders and gait abnormalities.
General Practitioner Preferences in Managing Care of Multiple Sclerosis Patients.
Multiple Sclerosis from Bench to Bedside.
New data presented at 29th ECTRIMS congress reinforce the clinical profile of investigational laquinimod on disease progression and inflammation in relapsing-remitting multiple sclerosis
[A different approach to the care of patients with MS].
Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment.
MicroRNA-21 with therapeutic potential in autoimmune diseases.
Nitric oxide inhibits CXCL12 expression in neuroinflammation.
Perception of affective prosody in patients at an early stage of relapsing-remitting multiple sclerosis.
Induction of Heat Shock Protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun.
Autoimmune neurological disorders associated with group-A beta-hemolytic streptococcal infection.
Sleep loss as risk factor for neurologic disorders: A review.
Oxidative stress and neurodegenerative disease.
Multiple Sites of the Cleavage of 21- and 25-Mer Encephalytogenic Oligopeptides Corresponding to Human Myelin Basic Protein (MBP) by Specific Anti-MBP Antibodies from Patients with Systemic Lupus Erythematosus.
Available evidence and outcome of off-label use of rituximab in clinical practice.
Self-rating makes the difference: Identifying palliative care needs of patients feeling severely affected by multiple sclerosis.
Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
Fluoxetin Upregulates Connexin 43 Expression in Astrocyte.
Reply to Article: High inbreeding in the Faroe Islands does not appear to constitute a risk factor for multiple sclerosis.
Pages
« first
‹ previous
…
296
297
298
299
300
301
302
303
304
…
next ›
last »